Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed results from two Phase 3 trials in adults with recurring severe chronic rhinosinusitis with nasal polyps (CRSwNP ...

In the EVEREST trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE ...